Response to: Efficacy of Brigatinib After Progression on Alectinib or Ceritinib: Does One Drug Work in a Pretreated Heterogeneous ALK-Positive NSCLC Population?
暂无分享，去创建一个
[1] Edward S. Kim,et al. Efficacy of Brigatinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Who Progressed on Alectinib or Ceritinib: ALTA-2 Study. , 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[2] J. Shih,et al. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing. , 2021, European journal of cancer.
[3] Y. Ohe,et al. Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[4] D. Planchard,et al. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non–Small-Cell Lung Cancer , 2019, Clinical Cancer Research.
[5] Yi-long Wu,et al. Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer , 2018, Thoracic cancer.